Stomach Medicines — Medication Guide, Uses & Safety — Uses, Dosage & Side Effects | MyMedicPlus

Stomach medicines encompass a broad range of drug classes used to treat the many conditions affecting the gastrointestinal (GI) tract — from the esophagus and stomach through to the small and large intestine. Gastrointestinal disorders are among the most common reasons for medical consultations worldwide, affecting over 40% of the global population at some point. Major categories of stomach medicines include: acid-reducing medications (antacids for immediate neutralization; H2 receptor antagonists for moderate acid suppression; proton pump inhibitors/PPIs such as omeprazole for powerful sustained acid suppression); motility-modifying agents (prokinetics such as metoclopramide and domperidone for nausea and gastric emptying; antispasmodics such as hyoscine butylbromide and mebeverine for IBS cramping); bowel-regulating agents (bulk-forming, osmotic, stimulant laxatives for constipation; loperamide and bismuth subsalicylate for diarrhea); and antiemetics (ondansetron, cyclizine, prochlorperazine, hyoscine for nausea and vomiting). Specific GI disease treatments include aminosalicylates (mesalazine) and immunosuppressants for inflammatory bowel disease (Crohn's disease, ulcerative colitis), and rifaximin for irritable bowel syndrome with diarrhea. GI medicines are prescribed or recommended by gastroenterologists, general practitioners, pharmacists, and emergency physicians across a huge range of clinical contexts.

GI medicines treat a broad spectrum of upper and lower gastrointestinal conditions. Upper GI conditions: gastroesophageal reflux disease (GERD) — treated with lifestyle modification, antacids (acute relief), H2 blockers (famotidine — moderate suppression), and PPIs (omeprazole, pantoprazole, lansoprazole — for erosive esophagitis, maintenance therapy); gastric and duodenal peptic ulcers — treated with PPIs (4–8 weeks) and Helicobacter pylori eradication therapy (triple therapy: PPI + clarithromycin + amoxicillin, or quadruple therapy in clarithromycin-resistant areas) in H. pylori-positive patients; gastroparesis (delayed gastric emptying) — treated with prokinetics (metoclopramide, domperidone) and dietary modification. Nausea and vomiting: from gastroenteritis, motion sickness (hyoscine/cinnarizine), chemotherapy-induced nausea and vomiting (CINV — ondansetron is first-line), pregnancy-related nausea (pyridoxine, ginger, antihistamines, prochlorperazine), and post-operative nausea. Lower GI conditions: irritable bowel syndrome (IBS) — treated with antispasmodics (mebeverine, hyoscine butylbromide, peppermint oil), low-FODMAP diet, bulk-forming agents (ispaghula husk), loperamide (IBS-D), and linaclotide or lubiprostone (IBS-C); Crohn's disease and ulcerative colitis — aminosalicylates, corticosteroids (acute flares), immunomodulators (azathioprine, 6-MP), and biologics (infliximab, adalimumab, vedolizumab); constipation — bulk-forming (ispaghula), osmotic (lactulose, macrogol/polyethylene glycol), stimulant (senna, bisacodyl) laxatives; acute diarrhea — loperamide (OTC), oral rehydration salts.

GI drugs work through highly specific mechanisms targeting different parts of the gastrointestinal system. PPIs (omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole) irreversibly inhibit the H+/K+-ATPase proton pump in gastric parietal cells — the enzyme directly responsible for secreting hydrochloric acid — reducing acid output by 80–95%, allowing inflamed and ulcerated mucosal surfaces to heal. H2 receptor antagonists (famotidine, ranitidine [withdrawn], cimetidine) competitively block histamine H2 receptors on parietal cells, reducing acid secretion by approximately 70% during the daytime and 90% at night — effective but shorter-lasting and less potent than PPIs. Prokinetics: metoclopramide and domperidone block dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastric wall — reducing nausea and accelerating gastric emptying; domperidone also blocks the CTZ peripherally without crossing the blood-brain barrier (reducing extrapyramidal motor side effects compared to metoclopramide). Ondansetron is a selective 5-HT3 serotonin receptor antagonist — blocking peripheral serotonin receptors in the GI tract and central CTZ that trigger chemotherapy-induced and other forms of severe nausea. Antispasmodics (hyoscine butylbromide/Buscopan, mebeverine, peppermint oil) relax GI smooth muscle by blocking muscarinic acetylcholine receptors or directly relaxing smooth muscle, reducing crampy abdominal pain from bowel spasm in IBS. Loperamide binds to opioid mu receptors in the myenteric plexus of the gut wall, reducing peristaltic activity and intestinal motility, increasing transit time and allowing fluid reabsorption — without significant CNS effects at normal doses.

Doses vary significantly by drug class and indication. PPIs: omeprazole 20 mg once daily before breakfast for GERD symptom relief; 40 mg once daily for erosive esophagitis or gastric ulcer; lansoprazole 15–30 mg once daily; pantoprazole 20–40 mg once daily. H2 blockers: famotidine 20 mg twice daily (OTC: 10–20 mg); 40 mg at night for duodenal ulcer healing. Metoclopramide: 10 mg three times daily, 30 minutes before meals (maximum 5 days of use). Domperidone: 10 mg three times daily, 30 minutes before meals (max 10 mg three times daily; not recommended over 1 week; not in those over 60 or with cardiac conditions without specialist input). Ondansetron: 4–8 mg orally or IV every 8 hours for CINV or post-operative nausea. Hyoscine butylbromide (Buscopan): 10–20 mg 3–4 times daily for IBS spasm. Mebeverine: 135–200 mg three times daily 20 minutes before meals for IBS. Loperamide: 2 mg after the first loose stool, then 2 mg after each subsequent loose stool (max 16 mg/day in adults; max 8 mg/day OTC; do not use for more than 2 days in acute diarrhea without medical advice). Lactulose for constipation: 15–45 mL once or twice daily. Macrogol (Movicol): 1–3 sachets daily in divided doses in water. Always follow your doctor's or pharmacist's specific instructions for each GI medicine.

PPIs (omeprazole, pantoprazole, lansoprazole): commonly cause headache (5%), nausea, abdominal pain, diarrhea, and flatulence. Long-term use (more than 1 year) is associated with: hypomagnesemia (low magnesium — causing muscle cramps, cardiac arrhythmias, and tetany); vitamin B12 malabsorption (impaired food-bound B12 digestion due to acid suppression); modestly increased fracture risk (hip, wrist, spine — calcium and vitamin D supplementation is recommended for long-term users); increased risk of Clostridioides difficile and community-acquired pneumonia; and development of fundic gland polyps (usually benign). PPI-associated acute interstitial nephritis (a drug hypersensitivity reaction) is rare but requires drug discontinuation if confirmed. H2 blockers: generally very well tolerated; cimetidine (now rarely used) has multiple significant drug interactions via CYP enzyme inhibition; confusion and CNS effects can occur in the elderly at higher doses. Metoclopramide: significant CNS side effects including drowsiness (15%), restlessness (akathisia — 10%), and — with long-term or high cumulative dose use — tardive dyskinesia (potentially irreversible involuntary repetitive movements of the face and limbs). The MHRA and FDA restrict metoclopramide to a maximum of 5 consecutive days to minimize this risk. The maximum dose is 0.5 mg/kg/day. Domperidone: less CNS penetration than metoclopramide, but FDA withdrew it in some markets due to cardiac concerns (QT prolongation — increased risk of ventricular arrhythmia, particularly at higher doses, in elderly patients, and with QT-prolonging drug combinations). Restrict to lowest effective dose (10 mg) for shortest time. Ondansetron: headache (most common), constipation, QT prolongation at high doses. Loperamide: constipation and abdominal distension with continued use; at supratherapeutic doses (abuse) can cause life-threatening cardiac arrhythmias — FDA safety warning issued; must not be used in invasive bacterial diarrhea (with high fever or blood in stools) or in toxic megacolon.

Metoclopramide must not be used for more than 5 consecutive days due to the significant and potentially irreversible risk of tardive dyskinesia (a movement disorder). Loperamide must not be used if bloody stools (dysentery), fever above 38°C, or signs of severe colitis are present — in confirmed or suspected invasive bacterial gastroenteritis (salmonella, shigella, campylobacter, C. difficile), loperamide can inhibit the bacterial clearance mechanism and worsen infection, potentially causing toxic megacolon — seek medical assessment for diarrhea with these features instead of self-treating. Do not self-treat recurrent, chronic, or unexplained gastrointestinal symptoms — persistent abdominal pain, blood in stools (even small amounts), unexplained weight loss, difficulty or pain on swallowing (dysphagia), vomiting that is persistent or blood-stained, and a change in bowel habit lasting more than 6 weeks all require urgent medical evaluation to exclude serious pathology including colorectal cancer, gastric cancer, and inflammatory bowel disease. Long-term PPI use should be regularly reviewed — step-down to on-demand or lowest-dose maintenance should be attempted annually. Key drug interactions for GI medicines: domperidone and ondansetron can prolong the QT interval — avoid with other QT-prolonging drugs (macrolide antibiotics, antipsychotics, antiarrhythmics); omeprazole (CYP2C19 inhibitor) reduces the antiplatelet efficacy of clopidogrel by up to 45% — use pantoprazole instead for patients on clopidogrel; antacids significantly reduce absorption of many drugs (thyroid hormone, antibiotics, bisphosphonates) — administer other medicines at least 2 hours apart; laxatives (stimulant/osmotic) can cause significant electrolyte imbalances with excessive use — monitor potassium in elderly patients on laxatives.